news agency

Vaccinated with Sinovac receive strong boost with COVID injections from Pfizer, AstraZeneca or J&J, according to study

A third booster dose with a COVID-19 vaccine produced by AstraZeneca, Pfizer-BioNTech, or Johnson & Johnson (J&J) significantly increases the antibody levels of those who previously received two doses of Sinovac’s CoronaVac injection, according to a study.

The study revealed that CoronaVac received the greatest boost from a viral vector or mRNA injection, even against delta and omicron variants of the coronavirus, researchers from Brazil and the University of Oxford said.

The China-based company Sinovac’s vaccine uses an inactivated, or killed, version of a coronavirus strain that was isolated from a patient in China. It is currently approved in more than 50 countries, including Brazil, Chile, China, Argentina, South Africa and Turkey.

“This study offers important options for policy makers in the many countries where inactivated vaccines have been used,” said Andrew Pollard, director of the Oxford Vaccine Group, who led the study.

However, another study in December found that injection of two doses of Sinovac followed by a booster dose of the Pfizer-BioNTech vaccine showed a lower immune response against the omicron variant compared to other mutations.

Viral-vectored vaccines, such as those developed by AstraZeneca-Oxford and J&J, use a weakened version of another virus to deliver the proteins of the virus being protected against.

Pfizer and BioNTech’s mRNA vaccine teaches the body to make antibodies against infections using chemical signals.

A third dose of CoronaVac also raised antibodies, but results were better when a different vaccine was used, according to the latest study involving 1,240 volunteers from the Brazilian cities of Sao Paulo and Salvador.

.

You may also like

Hot News

TRENDING NEWS

Subscribe

follow us

Immediate Access Pro